Cytokines and Inflammatory Response in the Fetus and Neonate

Fetal and Neonatal Physiology: Third Edition

Volumn 2-2, Issue , 2003, Pages 1555-1572

  Kilpatrick, Laurie ^a   Harris, Mary Catherine ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 3242745488     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-9654-6.50162-4     Document Type: Chapter

References (317)

1. Pruitt JH, et al. Interleukin-1 and interleukin-1 antagonism in sepsis, systemic inflammatory response syndrome, and septic shock. Shock 1995, 3:235.
2. Moldawer LL Biology of pro-inflammatory cytokines and their antagonists. Crit Care Med 1994, 22:S3.
3. Lowry SF Cytokine mediators of immunity and inflammation. Arch Surg 1993, 128:1235.
4. Oberholzer A, et al. Cytokine signaling-regulation of the immune response in normal and critically ill states. Crit Care Med 2000, 28(Suppl 4):N3.
5. Strieter RM, et al. Role of tumor necrosis factor&-α in disease states and inflammation. Crit Care Med 1993, 21:S447.
6. van der Poll T, van Deventer SJH Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 1999, 13:413.
7. Opal SM, DePalo VA Anti-Inflammatory cytokines. Chest 2000, 117:1162.
8. Blackwell TS, Christman JW Sepsis and cytokines: current status. Br J Anaesth 1996, 77:110.
9. Pennica D, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984, 312:724.
10. Black RA, et al. A metalloproteinase disintegrin that releases tumor necrosis factor-alpha from cells. Nature 1997, 385:729.
11. Moss ML, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumor necrosis factor-alpha. Nature 1997, 385:733.
12. Kriegler M, et al. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications of complex physiology of TNF. Cell 1988, 53:45.
13. van der Poll T, Lowry SF Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense?. Shock 1995, 3:1.
14. Vilcek J, Lee TH Tumor necrosis factor: new insights into the molecular mechanisms of its multiple actions. J Biol Chem 1991, 266:7313.
15. Loetscher H, et al. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 1990, 61:351.
16. Schall TJ, et al. Molecular cloning and expression of a receptor for human TNF. Cell 1990, 61:361.
17. Dembic Z, et al. Two human TNF receptors have similar extracellular, but distinct intracellular domain sequences. Cytokine 1990, 2:231.
18. Beutler B, van Huffel C Unraveling function in the TNF ligand and receptor families. Science 1994, 264:667.
19. Tartaglia LA, Goeddel DV Two TNF receptors. Immunol Today 1992, 13:151.
20. Ashkenazi A, Dixit VM Death receptors: signaling and modulation. Science 1998, 28:1305.
21. Pfeffer K, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993, 73:457.
22. MacEwan DJ TNF receptor subtype signaling: differences and cellular consequences. Cell Signal 2002, 14:477.
23. Hsu H, et al. The TNF receptor-1-associated death domain protein TRADD signals cell death and NFκB activation. Cell 1995, 81:495.
24. Hsu H, et al. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996, 4:387.
25. Hsu H, et al. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996, 84:299.
26. Aggarwal BB Tumour necrosis factor receptor associated signaling molecules and their role in activation of apoptosis, JNK and NF&-κB. Ann Rheum Dis 2000, 59(Suppl I):i6.
27. Baeuerle PA Pro-inflammatory signaling: last pieces in the NF&-κB puzzle. Curr Biol 1998, 8:R19.
28. Barnes PJ, Karin M Mechanisms of disease: nuclear factor- (kappa)B-a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997, 336:1066.
29. Rothe J, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993, 364:794.
30. Erickson SL, et al. Decreased sensitivity to tumour necrosis factor but normal T-cell development in TNF receptor-2 deficient mice. Nature 1994, 372:560.
31. Dinarello CA, Wolff SM The role of interleukin-1 in disease. N Engl J Med 1993, 328:106.
32. Dinarello CA Interleukin-1. Cytokine Growth Fact Rev 1997, 8:253.
33. Webb AC, et al. Interleukin-1 gene (IL1) assigned to the long arm of human chromosome 2. Lymphokine Res 1986, 5:77.
34. Sims JE IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol 2002, 14:117.
35. Cerretti DP, et al. Molecular cloning of the interleukin-1β converting enzyme. Science 1992, 256:97.
36. Thornberry NA, et al. A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 1992, 356:768.
37. O'Neill LAJ The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Science's Stke (Electronic Resource): Signal Transduction Knowledge Environment 2000, (44). REI, 2000.
38. Fitzgerald KA, O'Neill LAJ The role of the interleukin-1/Toll-like receptor superfamily in inflammation and host defense. Microbes Infect 2000, 2:933.
39. Dinarello CA Pro-inflammatory cytokines. Chest 2000, 118:503.
40. Sims JE, et al. The two interleukin-1 receptors play different roles in IL-1 actions. Clin Immunol Immunopathol 1994, 72:9.
41. Matsushima K, et al. Properties of a specific interleukin-1 receptor on human Epstein-Barr virus transformed B lymphocytes: identity of the receptors for IL-1α and IL-1β. J Immunol 1986, 136:4496.
42. Muzio M, et al. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997, 278:1612.
43. Cao Z, et al. IRAK: a kinase associated with the interleukin-1 receptor. Science 1996, 271:1128.
44. Cao Z, et al. TRAF6 is a signal transducer for interleukin-1. Nature 1996, 383:443.
45. Barton BE IL-6: Insights into novel biological activities. Clin Immunol Immunopathol 1997, 85:16.
46. Jones SA, et al. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001, 15:43.
47. Sehgal PB Interleukin 6 in infection and cancer. Soc Exp Biol Med 1990, 195:183.
48. Mizel SB The interleukins. FASEB J 1989, 3:2379.
49. Bluethmann H, et al. Establishment of the role of IL-6 and TNF receptor 1 using gene knockout mice. J Leukoc Biol 1994, 56:565.
50. Yamasaki K, et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN β) receptor. Science 1988, 241:825.
51. Taga T, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989, 58:573.
52. Hirano T Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 1992, 62:S60.
53. Kishimoto T, et al. Interleukin-6 family of cytokines and gp130. Blood 1995, 86:1243.
54. Hirano T, et al. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Fact Rev 1997, 8:241.
55. Heinrich PC, et al. Interleukin-6-type cytokine signaling through the gp130/JAK/STAT pathway. Biochem J 1998, 334:297.
56. Taga T, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989, 58:573.
57. Stahl N, et al. Choice of STATs and other substrates specified by modular tyrosine based motifs in cytokine receptors. Science 1995, 267:1349.
58. Gerhartz C, et al. Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the IL-6 signal transducer gp130. Definition of a novel phosphotyrosine motif mediating STAT1 activation. J Biol Chem 1996, 271:12991.
59. Nakajima K, et al. Signal transduction through IL-6 receptor: involvement of multiple protein kinases, stat factors, and a novel H7-sensitive pathway. Ann NY Acad Sci 1995, 762:55.
60. Baggiolini M, Clark-Lewis I Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett 1992, 307:97.
61. Baggiolini M, et al. Neutrophil activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 1989, 84:1045.
62. Luster AD Mechanisms of disease: chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998, 338:436.
63. Keane MP, Strieter RM Chemokine signaling in inflammation. Crit Care Med 2000, 28(Suppl 4):N13.
64. Baggiolini M, et al. Human chemokines: an update. Annu Rev Immunol 1997, 15:675.
65. Hebert C, et al. Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding. J Biol Chem 1991, 266:18989.
66. Murdoch C, Finn A Chemokine receptors and their role in inflammation and infectious diseases. Blood 2000, 95:3032.
67. Holmes WE, et al. Structure and functional expression of a human interleukin-8 receptor. Science 1991, 253:1278.
68. Murphy PM, Tiffany HL Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science 1991, 253:1280.
69. Curnock AP, et al. Chemokine signaling: pivoting around multiple phosphoinositide 3-kinases. Immunology 2002, 105:125.
70. Huang R, et al. Neutrophils stimulated with a variety of chemoattractants exhibit rapid activation of p21-activated kinases (Paks): separate signals are required for activation and inactivation of paks. Mol Cell Biol 1998, 18:7130.
71. Jones SA, et al. A comparison of post-receptor signal transduction events in Jurkat cell transfected with either IL-8R1 or IL-8R2: chemokine mediated activation of p42/p44 MAP-kinase (ERK-2). FEBS Lett 1995, 364:211.
72. Laudanna C, et al. Role of Rho in chemoattractant-activated leukocyte adhesion through integrins. Science 1996, 271:981.
73. Norgauer J, et al. Actin polymerization, calcium transient, and phospholipid metabolism in human neutrophils after stimulation with interleukin-8 and N-formyl peptide. J Invest Dermatol 1994, 102:310.
74. Kettritz R, et al. Interleukin-8 delays spontaneous and tumor necrosis factor&-α-mediated apoptosis in human neutrophils. Kidney Internat 1998, 53:84.
75. Richardson DM, et al. Regulation of human interleukin-8 receptor A: identification of a phosphorylation site involved in modulating receptor functions. Biochemistry 1995, 34:14193.
76. Colombo MP, Trinchieri G Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002, 13:155.
77. Trinchieri G Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN&-γ). Curr Opin Immunol 1997, 9:17.
78. Merberg DM, et al. Sequence similarity between NKSF and the IL-6/G-CSF family. Immunol Today 1992, 13:77.
79. Gearling DP, Cosman D Homology of the p40 subunit of natural killer cell stimulatory factor (NSFK) with the extracellular domain of the interleukin-6 receptor. Cell 1991, 66:9.
80. Romani L, et al. Interleukin-12 in infectious diseases. Clin Microbiol Rev 1997, 10:611.
81. Karp CL, Wills-Karp M Complement and IL-12: yin and yang. Microbes Infect 2001, 3:109.
82. Presky DH, et al. A functional interleukin 12 receptor complex is composed of two β type cytokine receptor subunits. Proc Natl Acad Sci USA 1996, 93:14002.
83. Bacon CM, et al. Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of janus family tyrosine kinases by IL-2 and IL-12. J Exp Med 1995, 181:399.
84. Dorman SE, Holland SM Interferon&-γ and interleukin-12 pathway defects and human disease. Cytokines Growth Rev 2000, 11:321.
85. Ramana CV, et al. Stat-1-dependent and -independent pathways in IFN&-γ-dependent signaling. Immunol Trends 2002, 23:96.
86. Bach EA, et al. The IFNγ receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997, 15:563.
87. Boehm U, et al. Cellular responses to interferon&-γ. Annu Rev Immunol 1997, 15:749.
88. Darnell JE, et al. JAK-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415.
89. Okamura H, et al. Cloning of a new cytokine that induces IFN&-γ production by T cells. Nature 1995, 378:88.
90. Akira S The role of IL-18 in innate immunity. Curr Opin Immunol 2000, 12:59.
91. Bazan JF, et al. A newly defined interleukin-1?. Nature 1996, 379:591.
92. Ghayur T, et al. Caspase-1 processes IFN&-γ-inducing factor and regulates LPS-induced IFN&-γ production. Nature 1997, 386:619.
93. Gu Y, et al. Activation of interferon&-γ- inducing factor mediated by IL-1β converting enzyme. Science 1997, 275:206.
94. Dinarello CA Interleukin-18. Methods 1999, 19:121.
95. Gillespie MT, Horwood NJ Interleukin-18: perspectives on the newest interleukin. Cytokine Growth Factor Rev 1998, 9:109.
96. Leung BP, et al. A role for IL-18 in neutrophil activation. J Immunol 2001, 167:2879.
97. Fiorentino DF, et al. Two types of mouse T-helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989, 170:2081.
98. Oberholzer A, et al. Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 2002, 30(Suppl 1):S58.
99. Asadullah K, et al. Interleukin-10 in cutaneous disorders: implications for its pathological importance and therapeutic use. Arch Dermatol Res 1999, 291:628.
100. Moore KW, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683.
101. Opal SM, et al. Interleukin-10: potential benefits and possible risks in clinical infectious diseases. Clin Infect Dis 1998, 27:1497.
102. Akdis CA, Blaser K Mechanisms of interleukin-10 mediated immune suppression. Immunology 2001, 103:131.
103. Ho ASY, et al. A receptor for IL-10 is related to interferon receptors. Proc Natl Acad Sci USA 1993, 90:11267.
104. Finbloom DS, Winestock KD IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1α and STAT3 complexes in human T cells and monocytes. J Immunol 1995, 155:1079.
105. Wang P, et al. Interleukin (IL)-10 inhibits nuclear factor kappa B (NFkappaB) activation in human monocytes: IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995, 270:9558.
106. McKenzie A, et al. Interleukin-13, a T-cell derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci USA 1993, 90:3735.
107. Hu-Li J, et al. B cell stimulatory factor-1 (interleukin-4) is a potent costimulant for normal resting T lymphocytes. J Exp Med 1987, 165:157.
108. Brubaker JO, Montaner LJ Role of interleukin-13 in innate and adaptive immunity. Cell Mol Biol 2001, 47:637.
109. Brombacher F The role of interleukin-13 in infectious diseases and allergy. Bioessays 2000, 22:646.
110. Koj A Termination of the acute-phase response: role of some cytokines and anti-inflammatory drugs. Gen Pharmacol 1998, 31:9.
111. Matsukawa A, et al. Expression and contribution of endogenous IL-13 in an experimental model of sepsis. J Immunol 2000, 164:2738.
112. Callard RE, et al. IL-4 and IL-13 receptors: are they one and the same?. Immunol Today 1996, 17:108.
113. Nelms K, et al. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999, 17:701.
114. Jiang H, et al. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol 2000, 105:1063.
115. McKenzie ANJ Regulation of T helper type 2 cell immunity by interleukin-4 and interleukin-13. Pharmacol Ther 2000, 88:143.
116. Caput D, et al. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain. J Biol Chem 1996, 271:16921.
117. Keegan A, et al. Similarities and differences in signal transduction by interleukin-4 and interleukin-13 analysis of Janus kinase activation. Proc Natl Acad Sci USA 1995, 92:7681.
118. Lin J-X, et al. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13 and IL-15. Immunity 1995, 2:331.
119. Zamorano J, et al. IL-4 protects cells from apoptosis via the insulin receptor substrate pathway and a second independent signaling pathway. J Immunol 1996, 157:4926.
120. Manna SK, Aggarwal BB Interleukin-4 down regulates both forms of tumor necrosis factor receptor and receptor mediated apoptosis, NF-kappaB, AP-1 and c-Jun N-terminal kinase. Comparison with interleukin-13. J Biol Chem 1998, 273:33333.
121. Paul SR, et al. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 1990, 87:7512.
122. Leng SX, Elias JA Interleukin-11. Int J Biochem 1997, 29:1059.
123. Du X, Williams DA Interleukin-11: review of molecular, cell biology, and clinical use. Blood 1997, 89:3897.
124. Zheng T, et al. IL-11: insights in asthma from overexpression transgenic modeling. J Allergy Clin Immunol 2001, 108:489.
125. Trepicchio WL, et al. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of pro-inflammatory cytokine release and nitric oxide production. J Immunol 1996, 157:3627.
126. Baumann H, Schendel P Interleukin-11 regulates the hepatic expression of the same plasma protein genes as interleukin-6. J Biol Chem 1991, 266:20424.
127. Trepicchio WL, et al. IL-11 regulates macrophage effector function through the inhibition of nuclear factor&-κB. J Immunol 1997, 159:5661.
128. Zhang XG, et al. Cilary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using interleukin 6 signal transducer gp 130. J Exp Med 1994, 179:1337.
129. Hilton DJ, et al. Cloning of a murine IL-11 receptor alpha-chain; requirement for gp130 for high affinity binding and signal transduction. EMBO J 1994, 13:4765.
130. Barton VA, et al. Interleukin-11 signals through the formation of a hexameric receptor complex. J Biol Chem 2000, 275:36197.
131. Dahmen H, et al. Activation of the signal transducer gp130 by interleukin-11 and interleukin-6 is mediated by similar molecular interactions. Biochem J 1998, 331:695.
132. Aderka D The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996, 7:231.
133. Engelmann H, et al. Two tumor necrosis factor binding proteins purified from human urine: evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990, 265:1531.
134. Dri P, et al. TNF-induced shedding of TNF receptors in human polymorphonuclear leukocytes: role of the 55-kDa TNF receptor and involvement of a membrane-bound and non-matrix metalloproteinase. J Immunol 2000, 165:2165.
135. Seckinger P, et al. A human inhibitor of tumor necrosis factor alpha. J Exp Med 1988, 167:1511.
136. Schluter D, Deckert M The divergent role of tumor necrosis factor receptors in infectious diseases. Microbes Infect 2000, 2:1285.
137. Pinckard JK, et al. Constitutive shedding of both p55 and p75 murine TNF receptor in vivo. J Immunol 1997, 158:3869.
138. VanZee KJ, et al. Tumor necrosis factor soluble receptor circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA 1992, 89:4845.
139. van der Poll T, et al. Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis 1993, 168:955.
140. Girardin E, et al. Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunology 1992, 76:20.
141. Arend WP, et al. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998, 16:27.
142. Evans RJ, et al. Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and IL-1β by site directed mutagenesis: identification of a single site in IL-1ra and two sites in IL-1β. J Biol Chem 1995, 270:11477.
143. Greenfeder SA, et al. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem 1995, 270:13757.
144. Granowitz EV, et al. Production of interleukin-1 receptor antagonist during experimental endotoxemia. Lancet 1991, 338:1423.
145. Mantovani A, et al. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol 2001, 22:328.
146. Giri JG, et al. Elevated levels of shed type II IL-1 receptors in sepsis: potential role for type II receptor in regulation of IL-1 response. J Immunol 1994, 153:5802.
147. Pruitt JH, et al. Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome. Blood 1996, 87:3282.
148. Orlando S, et al. Role of metalloproteases in the release of the IL-1 type II decoy receptor. J Biol Chem 1997, 272:31764.
149. Novick D, et al. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999, 10:127.
150. Novick D, et al. A novel IL-18bp ELISA shows elevated serum IL-18bp in sepsis and extensive decrease of free IL-18. Cytokine 2001, 14:334.
151. Dinarello CA Targeting interleukin 18 with interleukin 18 binding protein. Ann Rheum Dis 2000, 59(Suppl 1):17.
152. Faggioni R, et al. IL-18 binding protein protects against lipopolysaccharide-induced lethality and prevents development of Fas/Fas ligand-mediated models of liver disease in mice. J Immunol 2001, 167:5913.
153. Baggiolini M, Dahinden CA CC chemokines in allergic inflammation. Immunol Today 1994, 15:127.
154. Reinhart K, et al. Marker of endothelial damage in organ dysfunction and sepsis. Crit Care Med 2002, 30:S302.
155. Strieter RM, et al. Chemokines in lung injury. Chest 1999, 116(Suppl 1):1035.
156. Dallegri F, Ottonello L Tissue injury in neutrophilic inflammation. Inflamm Res 1997, 46:382.
157. Bellingan G Leukocytes: friend or foe. Intensive Care Med 2000, 26:S111.
158. Springer TA Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76:301.
159. Strieter RM, et al. Cytokines and lung inflammation: mechanisms of neutrophil recruitment to the lung. Thorax 1993, 48:765.
160. Aderem AA How cytokines signal messages within cells. J Clin Invest 1993, 167(Suppl 1):S2.
161. McLeish KR, et al. Modulation of transmembrane signalling in HL-60 granulocytes by tumour necrosis factor&-α. Biochem J 1991, 279:455.
162. Nathan CF Neutrophil activation on biological surfaces: massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. J Clin Invest 1987, 80:1550.
163. Kilpatrick LE, et al. Serine phosphorylation of p60 tumor necrosis factor by PKC&-δ in TNF&-α -activated neutrophils. Am J Physiol 2000, 279:C2011.
164. Bulger EM, Maier RV Lipid mediators in the pathophysiology of critical illness. Crit Care Med 2000, 28:N27.
165. Bussolino F, et al. Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1α. J Biol Chem 1988, 263:11856.
166. Davies MG, Hagen PO Systemic inflammatory response syndrome. Br J Surg 1997, 84:920.
167. Levy R, et al. Elevated cytosolic phospholipase A2 expression and activity in human neutrophils during sepsis. Blood 2000, 95:660.
168. Kerr JFR, et al. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972, 26:239.
169. Whyte MKB, et al. Impairment of function in aging neutrophils is associated with apoptosis. J Immunol 1993, 150:5124.
170. Kilpatrick LE, et al. A role for PKC&-δ and PI3-kinase in TNF&-α-mediated antiapoptotic signaling in the human neutrophil. Am J Physiol 2002, 283:C48.
171. Akgul C, et al. Molecular control of neutrophil apoptosis. FEBS Lett 2001, 487:318.
172. Marshall JC Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001, 29:S99.
173. Dhainaut J-F, et al. Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis. Crit Care Med 2002, 30:S318.
174. Shebuski RJ, Kilgore KS Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002, 300:729.
175. Van Gorp ECM, et al. Infectious diseases and coagulation disorders. J Infect Dis 1999, 180:176.
176. Portieje JEA, et al. Interleukin 12 induces activation of fibrinolysis and coagulation in humans. Br J Haematol 2001, 112:499.
177. Neumann F-J, et al. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulation activity. Arterioscler Thromb Vasc Biol 1997, 17:3399.
178. Cicala C, Cirino G Linkage between inflammation and coagulation: an update on the molecular basis of the crosstalk. Life Sci 1998, 62:1817.
179. Schleef RR, et al. Cytokine activation of vascular endothelium: effects of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 1988, 263:5797.
180. Levi M, et al. Endothelium: interface between coagulation and inflammation. Crit Care Med 2002, 30:S220.
181. Karima R, et al. The molecular pathogenesis of endotoxic shock and organ failure. Mol Med Today 1999, 5:123.
182. Opal S, et al. Roundtable I: relationships between coagulation and inflammatory processes. Crit Care Med 2000, 28:S81.
183. Pajkrt D, et al. Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood 1997, 89:2701.
184. Dinarello CA, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986, 163:1433.
185. Netea MG, et al. Circulating cytokines as mediators of fever. Clin Infect Dis 2000, 31:S178.
186. 3. Nature 1998, 395:281.
187. Gatti S, et al. Effect of interleukin-18 on mouse core body temperature. Am J Physiol 2002, 282:R702.
188. Baumann H, Schendel P Inerleukin-11 regulates hepatic expression of the same plasma protein genes as interleukin-6. J Biol Chem 1991, 266:20424.
189. Trepicchio WL, Dorner AJ Interleukin-11-a gp130 cytokine. Ann NY Acad Sci 1998, 856:12.
190. Tatro JB Endogenous antipyretics. Clin Infect Dis 2000, 31:S190.
191. Bluethmann H, et al. Establishment of the role of IL-6 and TNF receptor 1 using gene knockout mice. J Leukoc Biol 1994, 56:565.
192. Moshage H Cytokines and the hepatic acute phase response. J Pathol 1997, 181:257.
193. Kopf M, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994, 368:339.
194. Gabay C, Kushner I Mechanisms of disease: acute phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448.
195. Dhainaut J-F, et al. Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit Care Med 2001, 29:S42.
196. Jensen LE, Whitehead AS Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J 1998, 334:489.
197. Loyer P, et al. Interleukin 4 inhibits the production of some acute-phase proteins in human hepatocytes in primary culture. FEBS Lett 1993, 336:215.
198. Tilg H, et al. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 1997, 18:428.
199. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864.
200. van Deventer SJH Cytokine and cytokine receptor polymorphisms in infectious disease. Intensive Care Med 2000, 26:S98.
201. Klein JO, Marcy SM Bacterial sepsis and meningitis. Infectious Diseases of the Fetus and Newborn Infant 1995, 835-890. WB Saunders, Philadelphia. 4th ed. J.S. Remington, J.O. Klein (Eds.).
202. Harris MC, Polin RA Diagnosis of neonatal sepsis. Intensive Care of the Fetus and Neonate 2003, CV Mosby, St. Louis. A.R. Spitzer (Ed.).
203. Harris MC, Casey J Prevention and treatment of neonatal sepsis. Intensive Care of the Fetus and Neonate 2003, CV Mosby, St. Louis. A.R. Spitzer (Ed.).
204. Philip AGS Defense mechanisms and deficiencies. Neonatal Sepsis and Meningitis 1985, 29-42. GK Hall, Boston. A.G.S. Philip (Ed.).
205. Wilson CB Immunologic basis for increased susceptibility of the neonate to infection. J Pediatr 1986, 108:1.
206. Nesin M, Cunningham-Rundles S Cytokines and neonates. Am J Perinatol 2000, 17:393.
207. Slayton W Development of the immune system in the human fetus. Hematologic Problems of the Neonate 2000, 21-41. WB Saunders, Philadelphia. R.D. Christensen (Ed.).
208. Schultz C, et al. Enhanced interleukin-6 and interleukin-8 synthesis in term and preterm infants. Pediatr Res 2002, 51:317.
209. Jones CA, et al. Undetectable interleukin (IL)-10 and persistent IL-8 expression early in hyaline membrane disease: a possible developmental basis for the predisposition to chronic lung inflammation in preterm newborns. Pediatr Res 1996, 39:966.
210. Speer CP New insights into the pathogenesis of pulmonary inflammation in preterm infants. Biol Neonate 2001, 79:205.
211. Edelson MB, et al. Circulating pro- and counterinflammatory cytokine levels and severity in necrotizing enterocolitis. Pediatrics 1999, 103:766.
212. Giacoia GP New approaches for the treatment of neonatal sepsis. J Perinatol 1993, 13:223.
213. Saez-Llorens Z, Lagrutta SF The acute phase host reaction during bacterial infection and its clinical impact in children. Pediatr Infect Dis J 1993, 12:83.
214. Pennington JE Therapy with antibody to tumor necrosis factor in sepsis. Clin Infect Dis 1993, 17(Suppl 2):S515.
215. Fong YM, Lowry SF Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin Immunol Immunopathol 1990, 55:157.
216. Beutler B, Cerami A Cachectin: more than a tumor necrosis factor. N Engl J Med 1987, 316:379.
217. Kutteh WH, et al. Tumor necrosis factor&-α and interleukin-1β production by human fetal Kupffer cells. Am J Obstet Gynecol 1991, 165:112.
218. Kutteh WH, et al. Regulation of interleukin-6 production in human fetal Kupffer cells. Scand J Immunol 1991, 33:607.
219. Romero R, et al. Tumor necrosis factor in preterm and term labor. Am J Obstet Gynecol 1992, 166:1576.
220. Seghaye M-C, et al. The production of pro- and anti-inflammatory cytokines in neonates assessed by stimulated whole cord blood culture and by plasma levels at birth. Biol Neonate 1998, 73:220.
221. Peters AMJ, et al. Reduced secretion of interleukin-1 and tumor necrosis factor&-α by neonatal monocytes. Biol Neonate 1993, 63:157.
222. Weatherstone KB, Rich EA Tumor necrosis factor/cachectin and interleukin-1 secretion by cord blood monocytes from premature and term neonates. Pediatr Res 1989, 25:342.
223. English BK, et al. Production of lymphotoxin and tumor necrosis factor by human neonatal mononuclear cells. Pediatr Res 1988, 26:717.
224. Burchett SK, et al. Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes. J Immunol 1988, 140:3473.
225. Chheda S, et al. Decreased interleukin-10 production by neonatal monocytes and T cells: relationship to decreased production and expression of tumor necrosis factor&-α and its receptors. Pediatr Res 1996, 40:475.
226. Kwak DJ, et al. Intracellular and extracellular cytokine production by human mixed mononuclear cells in response to Group B streptococci. Infect Immun 2000, 68:320.
227. Hebra A, et al. Intracellular cytokine production by fetal and adult monocytes. J Pediatr Surg 2001, 36:1321.
228. Bessler H, et al. IL-1β and IL-3-like activity in preterm infants. Clin Exp Immunol 1993, 91:320.
229. Dinarello CA, et al. Production of leukocytic pyrogen from phagocytes of neonates. J Infect Dis 1981, 144:337.
230. Wilmott RW, et al. Interleukin-1 activity from human cord blood monocytes. Diagn Clin Immunol 1987, 5:201.
231. Srugo I, et al. Interleukin-1 secretion by blood monocytes of septic premature infants. Infection 1991, 19:150.
232. Bry K, et al. Influence of fetal gender on the concentration of interleukin-1 receptor antagonist in amniotic fluid and in newborn urine. Pediatr Res 1994, 35:130.
233. Contrino J, et al. Elevated interleukin-1 expression in human neonatal neutrophils. Pediatr Res 1993, 34:249.
234. Waage A, et al. TNF, IL-1 and IL-6 in human septic shock. Scand J Immunol 1988, 28:267.
235. Liechty KW, et al. Production of interleukin-6 by fetal and maternal cells in vivo during intraamniotic infection and in vitro after stimulation with interleukin-1. Pediatr Res 1991, 29:1.
236. Yachie A, et al. The capability of neonatal leukocytes to produce IL-6 on stimulation assessed by whole blood culture. Pediatr Res 1990, 27:227.
237. Yachie A, et al. Defective production of interleukin-6 in very small premature infants in response to bacterial pathogens. Infect Immunol 1992, 60:749.
238. Saito S, et al. Production of IL-6 (BSF-2/IFN β2) by mononuclear cells in premature and term infants. J Reprod Immunol 1990, 17:17.
239. Zola H, et al. Expression of cytokine receptors by human cord blood lymphocytes: comparison with adult blood lymphocytes. Pediatr Res 1995, 38:397.
240. Van Zee KJ, et al. IL-8 in septic shock, endotoxemia and after IL-1 administration. J Immunol 1991, 146:3478.
241. Taniguchi T, et al. Fetal mononuclear cells show a comparable capacity with maternal mononuclear cells to produce IL-8 in response to lipopolysaccharide in chorioamnionitis. J Reprod Immunol 1993, 23:1.
242. Dembinski J, et al. Cell-associated interleukin-8 in cord blood of term and preterm infants. Clin Diagn Lab Immunol 2002, 9:320.
243. 4 and interleukin-8 from human monocytes: neonates exhibit a diminished response. J Infect Dis 1995, 172:420.
244. Schibler KR, et al. Diminished transcription of interleukin-8 by monocytes from preterm neonates. J Leukoc Biol 1993, 53:399.
245. Roth I, et al. Human placental cytotrophoblasts produce the immunosuppressive cytokine interleukin 10. J Exp Med 1996, 184:539.
246. Kotiranta-Ainamo A, et al. Interleukin-10 production by cord blood mononuclear cells. Pediatr Res 1997, 41:110.
247. Vigano A, et al. Differential development of type 1 and type 2 cytokines and β-chemokines in the ontogeny of healthy newborns. Biol Neonate 1999, 75:1.
248. Gaudet LM, Smith GN Cerebral palsy and chorioamnionitis: the inflammatory cytokine link. Obstet Gynecol Surg 2001, 56:433.
249. Saliba E, Henrot A Inflammatory mediators and neonatal brain damage. Biol Neonate 2001, 79:224.
250. Wu YW, Colford JM Chorioamnionitis as a risk factor for cerebral palsy: a meta-analysis. JAMA 2000, 284:1417.
251. Yoon BH, et al. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1β, and tumor necrosis factor&-α), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol 1997, 177:19.
252. Yoon BH, et al. The relationship among inflammatory lesions of the umbilical cord (funisitis), umbilical cord plasma interleukin 6 concentration, amniotic fluid infection, and neonatal sepsis. Am J Obstet Gynecol 2000, 183:1124.
253. Dammann O, Leviton A Role of the fetus in perinatal infection and neonatal brain damage. Curr Opin Pediatr 2000, 12:99.
254. Yoon BH, et al. Fetal exposure to an intra-amniotic inflammation and the development of cerebral palsy at the age of three years. Am J Obstet Gynecol 2000, 182:675.
255. Gomez R, et al. The fetal inflammatory response syndrome. Am J Obstet Gynecol 1998, 179:194.
256. Chaiworapongsa T, et al. Evidence for fetal involvement in the pathologic process of clinical chorioamnionitis. Am J Obstet Gynecol 2002, 186:1178.
257. Yoon BH, et al. Fetal exposure to an intra-amniotic inflammation and the development of cerebral palsy at the age of three years. Am J Obstet Gynecol 2000, 182:675.
258. Gilstrap LC, Ramin SM Infection and cerebral palsy. Semin Perinatol 2000, 24:200.
259. Yoon BH, et al. Interleukin-6 concentrations in umbilical cord plasma are elevated in neonates with white matter lesions associated with periventricular leukomalacia. Am J Obstet Gynecol 1996, 174:1433.
260. Shimoya K, et al. Interleukin-8 in cord sera: a sensitive and specific marker for the detection of preterm chorioamnionitis. J Infect Dis 1992, 165:957.
261. Dammann O, Leviton A Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res 1997, 42:1.
262. Yanowitz TD, et al. Hemodynamic disturbances in premature infants born after chorioamnionitis: association with cord blood cytokine concentrations. Pediatr Res 2002, 51:310.
263. Duggan PJ, et al. Intrauterine T-cell activation and increased pro-inflammatory cytokine concentrations in preterm infants with cerebral lesions. Lancet 2001, 358:1699.
264. Dammann O, et al. Modification of the infection-associated risks of preterm birth and white matter damage in the preterm newborn by polymorphisms in the tumor necrosis factor-locus?. Pathogenesis 1999, 1:171.
265. Sullivan JS, et al. Correlation of plasma cytokine elevations with mortality rate in children with sepsis. J Pediatr 1992, 120:510.
266. Kaufman D, et al. Elevations of interleukin-8 in infants with bacterial sepsis. Pediatr Res 1996, 39:296A.
267. Girardin E, et al. Tumor necrosis factor in neonatal listeriosis: a case report. Eur J Pediatr 1989, 148:644.
268. Berner R, et al. Plasma levels and gene expression of granulocyte colony-stimulating factor, tumor necrosis factor&-α, interleukin (IL)-1β, IL-6, IL-8, and soluble intercellular adhesion molecule-1 in neonatal early onset sepsis. Pediatr Res 1998, 44:469.
269. Weimann E, et al. G-CSF, GM-CSF and IL-6 levels in cord blood: diminished increase of G-CSF and IL-6 in preterms with perinatal infection compared to term neonates. Perinat Med 1998, 26:211.
270. Girardin EP, et al. Serum tumor necrosis factor in newborns at risk for infections. Eur J Pediatr 1990, 149:645.
271. Roman J, et al. Serum TNF levels in neonatal sepsis and septic shock. Acta Paediatr 1993, 82:352.
272. Shi Y, et al. Plasma nitric oxide levels in newborn infants with sepsis. J Pediatr 1993, 123:435.
273. Miller LC, et al. Neonatal interleukin-1β, interleukin-6 and tumor necrosis factor: cord blood levels and cellular production. J Pediatr 1990, 117:961.
274. Büscher U, et al. IL-1β, IL-6, IL-8 and G-CSF in the diagnosis of early-onset neonatal infections. J Perinat Med 2000, 28:383.
275. Kashlan F, et al. Umbilical vein interleukin 6 and tumor necrosis factor alpha plasma concentrations in the very preterm infant. Pediatr Infect Dis J 2000, 19:238.
276. Nupponen I, et al. Neutrophil CD11b expression and circulating interleukin-8 as diagnostic markers for early-onset neonatal sepsis. Pediatrics 2001, 108:12.
277. Mehr SS, et al. Interleukin-6 and interleukin-8 in newborn bacterial infection. Am J Perinatol 2001, 18:313.
278. Berner R, et al. Elevated levels of lipopolysaccharide-binding protein and soluble CD14 in plasma in neonatal early-onset sepsis. Clin Diagn Lab Immunol 2002, 9:440.
279. Santana C, et al. Cord blood levels of cytokines as predictors of early neonatal sepsis. Acta Paediatr 2001, 90:1176.
280. Krueger M, et al. Cord blood levels of interleukin-6 and interleukin-8 for the immediate diagnosis of early-onset infection in premature infants. Biol Neonate 2001, 80:118.
281. Berner R, et al. Elevated gene expression of interleukin-8 in cord blood is a sensitive marker for neonatal infection. Eur J Pediatr 2000, 159:205.
282. Lehrnbecher T, et al. Immunologic parameters in cord blood indicating early-onset sepsis. Biol Neonate 1996, 70:206.
283. Døllner H, et al. Inflammatory mediators in umbilical plasma from neonates who develop early-onset sepsis. Biol Neonate 2001, 80:41.
284. DeBont ESJM, et al. Tumor necrosis factor&-α, interleukin-1β, and interleukin-6 plasma levels in neonatal sepsis. Pediatr Res 1993, 33:380.
285. Sikora JP, et al. Pro-inflammatory cytokines (IL-6, IL-8), cytokine inhibitors (IL-6sR, sTNFRII) and anti-inflammatory cytokines (IL-10, IL-13) in the pathogenesis of sepsis in newborns and infants. Arch Immunol Ther Exp (Warsz) 2001, 49:399.
286. Groll AH, et al. Interleukin-6 as early mediator in neonatal sepsis. Pediatr Infect Dis 1992, 11:496.
287. Edgar JDM, et al. Predictive value of soluble immunological mediators in neonatal infection. Clin Sci 1994, 87:165.
288. DeBont ESJM, et al. Diagnostic value of plasma levels of tumor necrosis factor α (TNFα) and interleukin-6 (IL-6) in newborns with sepsis. Acta Paediatr 1994, 83:696.
289. Buck C, et al. Interleukin-6: a sensitive parameter for the early diagnosis of neonatal bacterial infection. Pediatrics 1994, 93:54.
290. Mehr S, Doyle LW Cytokines as markers of bacterial sepsis in newborn infants: a review. Pediatr Infect Dis J 2000, 19:879.
291. Kliegman RM, Fanaroff AA Necrotizing enterocolitis. N Engl J Med 1984, 310:1093.
292. Caplan MS, MacKendrick W Inflammatory mediators and intestinal injury. Clin Perinatol 1994, 21:235.
293. Caplan MS, et al. Role of platelet activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis. J Pediatr 1990, 116:960.
294. Harris MC, et al. Cytokine elevations in critically ill infants with sepsis and necrotizing enterocolitis. J Pediatr 1994, 124:105.
295. Morecroft JA, et al. Plasma cytokine levels in necrotizing enterocolitis. Acta Paediatr 1994, 396(Suppl):18.
296. Harris MC, et al. Interleukin-8 levels (IL-8) in bacterial sepsis and necrotizing enterocolitis (NEC): correlation with clinical parameters of inflammation. Pediatr Res 2002, 51:140A.
297. Viscardi RM, et al. Inflammatory cytokine mRNAs in surgical specimens of necrotizing enterocolitis and normal newborn intestine. Pediatr Pathol Lab Med 1997, 17:547.
298. Nadler EP, et al. Intestinal cytokine gene expression in infants with acute necrotizing enterocolitis: interleukin-11 mRNA expression inversely correlates with extent of disease. J Pediatr Surg 2001, 36:1122.
299. McColm JR, et al. Measurement of interleukin 10 in bronchoalveolar lavage from preterm ventilated infants. Arch Dis Child 2000, 82:F156.
300. Hallman M Inflammatory pathways between placenta and foetus. Acta Pædiatr 2001, 90:1.
301. De Dooy JJ, et al. The role of inflammation in the development of chronic lung disease in neonates. Eur J Pediatr 2001, 160:457.
302. Jobe AH Intrauterine cytokine activation and the role of infection. Biol Neonate 2000, 78:244.
303. Yoon BH, et al. Amniotic fluid cytokines (interleukin-6, tumor necrosis factor&-α, interleukin-1, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 1997, 177:825.
304. Yoon BH, et al. A systemic fetal inflammatory response and the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 1999, 181:773.
305. Gähler A, et al. Interleukin-8 expression by fetal and neonatal pulmonary cells in hyaline membrane disease and amniotic infection. Pediatr Res 2000, 48:299.
306. Bagchi A, et al. Increased activity of interleukin-6 but not tumor necrosis factor&-α in lung lavage of premature infants is associated with the development of bronchopulmonary dysplasia. Pediatr Res 1994, 36:244.
307. Kotecha S Cytokines in chronic lung disease of prematurity. Eur J Pediatr 1996, 155(Suppl 2):S14.
308. Kazzi SNJ, et al. Serial changes in levels of IL-6 and IL-1β in premature infants at risk for bronchopulmonary dysplasia. Pediatr Pulmonol 2001, 31:220.
309. Huang H-C, et al. Profiles of inflammatory cytokines in bronchoalveolar lavage fluid from premature infants with respiratory distress disease. J Microbiol Immunol Infect 2000, 33:19.
310. Kwong KY, et al. Differential regulation of IL-8 by IL-1β And TNFα in hyaline membrane disease. J Clin Immunol 1998, 18:71.
311. Blahnik MJ, et al. Lipopolysaccharide-induced tumor necrosis factor&-α and IL-10 production by lung macrophages from preterm and term neonates. Pediatr Res 2001, 50:726.
312. Papoff P Infection, neutrophils, and hematopoietic growth factors in the pathogenesis of neonatal chronic lung disease. Clin Perinatol 2000, 27:717.
313. Manimtim WM, et al. Ureaplasma urealyticum modulates endotoxin-induced cytokine release by human monocytes derived from preterm and term newborns and adults. Infect Immun 2001, 69:3906.
314. Viscardi RM, et al. Lung pathology in premature infants with Ureaplasma urealyticum infection. Pediatr Dev Pathol 2002, 5:141.
315. Patterson AM, et al. Ureaplasma urealyticum respiratory tract colonization is associated with an increase in interleukin 1-beta and tumor necrosis factor alpha relative to interleukin 6 in tracheal aspirates of preterm infants. Pediatr Infect Dis J 1998, 17:321.
316. Li Y-H, et al. Ureaplasma urealyticum-induced production of pro-inflammatory cytokines by macrophages. Pediatr Res 2000, 48:114.
317. Baier RJ, et al. Monocyte chemoattractant protein-1 and interleukin-8 are increased in bronchopulmonary dysplasia: relation to isolation of Ureaplasma urealyticum. J Invest Med 2001, 49:362.